AU2001291526A1 - Sustained release composition containing clarithromycin - Google Patents
Sustained release composition containing clarithromycinInfo
- Publication number
- AU2001291526A1 AU2001291526A1 AU2001291526A AU9152601A AU2001291526A1 AU 2001291526 A1 AU2001291526 A1 AU 2001291526A1 AU 2001291526 A AU2001291526 A AU 2001291526A AU 9152601 A AU9152601 A AU 9152601A AU 2001291526 A1 AU2001291526 A1 AU 2001291526A1
- Authority
- AU
- Australia
- Prior art keywords
- sustained release
- clarithromycin
- release composition
- composition containing
- containing clarithromycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
A pharmaceutical oral sustained release composition of clarithromycin containing coated pellets comprising each a core containing clarithromycin and a sustained release coating surrounding the core, in which the sustained release coating comprises at least a water insoluble polymer which is substantially pH independent. Disclosed is a method of treating infection including a sustained release oral form of CLARITHROMYCIN constituted by coated pellets and allowing a once a day administration of the drug.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU73964/00 | 2000-09-22 | ||
BE0000112 | 2000-09-22 | ||
PCT/BE2001/000164 WO2002024174A2 (en) | 2000-09-22 | 2001-09-21 | Sustained release composition containing clarithromycin |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001291526A1 true AU2001291526A1 (en) | 2002-04-02 |
Family
ID=3862551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001291526A Abandoned AU2001291526A1 (en) | 2000-09-22 | 2001-09-21 | Sustained release composition containing clarithromycin |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040048814A1 (en) |
EP (1) | EP1318792B1 (en) |
AT (1) | ATE286387T1 (en) |
AU (1) | AU2001291526A1 (en) |
CA (1) | CA2423172A1 (en) |
DE (1) | DE60108255T2 (en) |
ES (1) | ES2234885T3 (en) |
PT (1) | PT1318792E (en) |
WO (1) | WO2002024174A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544555B2 (en) | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6565882B2 (en) * | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
WO2003037304A1 (en) * | 2001-11-02 | 2003-05-08 | Wockhardt Limited | Controlled release compositions for macrolide antimicrobial agents |
US7137696B2 (en) * | 2003-01-09 | 2006-11-21 | Con-Trol-Cure, Inc. | Ink jet UV curing |
WO2005004919A2 (en) * | 2003-07-02 | 2005-01-20 | Eurand, Inc. | Extended release systems for macrolide antibiotics |
EP1648418A4 (en) * | 2003-07-21 | 2011-11-16 | Middlebrook Pharmaceuticals Inc | Antibiotic product, use and formulation thereof |
CA2533292C (en) * | 2003-07-21 | 2013-12-31 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
AU2004258949B2 (en) * | 2003-07-21 | 2011-02-10 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
CA2535177A1 (en) * | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
EP1653924A4 (en) | 2003-08-12 | 2009-09-09 | Middlebrook Pharmaceuticals In | Antibiotic product, use and formulation thereof |
CA2535780A1 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
US8460710B2 (en) * | 2003-09-15 | 2013-06-11 | Shionogi, Inc. | Antibiotic product, use and formulation thereof |
JP2007517039A (en) * | 2003-12-24 | 2007-06-28 | アドバンシス ファーマスーティカル コーポレイション | Enhanced absorption of modified release formulations |
KR101122096B1 (en) * | 2004-05-20 | 2012-03-15 | 주식회사종근당 | Pharmaceutical composition of clarithromycin and its manufacturing method for taste masking and increasing dissolution rate |
CA2572292A1 (en) * | 2004-07-02 | 2006-02-09 | Advancis Pharmaceutical Corporation | Tablet for pulsed delivery |
CN1322866C (en) * | 2004-10-12 | 2007-06-27 | 广州贝氏药业有限公司 | Multi-unit slow-release preparation |
FR2879075B1 (en) * | 2004-12-15 | 2007-01-19 | Adisseo France Sas Soc Par Act | PROCESS FOR PREPARING EXTRUSION-ACTIVE HYDROPHILIC ACTIVE INGREDIENT PELLETS |
US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
KR100676075B1 (en) | 2005-02-17 | 2007-02-01 | 한국유나이티드제약 주식회사 | A Pellet Agent Containing Clarithromycin for oral suspension |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
US8778924B2 (en) | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US293885A (en) * | 1884-02-19 | Milton jackson | ||
US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
US4808411A (en) * | 1987-06-05 | 1989-02-28 | Abbott Laboratories | Antibiotic-polymer compositions |
CA2182282C (en) * | 1994-02-16 | 2006-04-18 | Jacqueline E. Briskin | Process for preparing fine particle pharmaceutical formulations |
AUPO637197A0 (en) * | 1997-04-23 | 1997-05-15 | F.H. Faulding & Co. Limited | Taste-masked pharmaceutical compositions |
WO2001035930A1 (en) * | 1999-11-16 | 2001-05-25 | Ranbaxy Laboratories Limited | Taste masked oral compositions |
JP2003523372A (en) * | 2000-02-24 | 2003-08-05 | アドバンシス ファーマシューティカル コーポレイション | Antibiotics and antifungal compositions |
-
2001
- 2001-09-21 PT PT01971528T patent/PT1318792E/en unknown
- 2001-09-21 WO PCT/BE2001/000164 patent/WO2002024174A2/en active IP Right Grant
- 2001-09-21 AU AU2001291526A patent/AU2001291526A1/en not_active Abandoned
- 2001-09-21 CA CA002423172A patent/CA2423172A1/en not_active Abandoned
- 2001-09-21 DE DE60108255T patent/DE60108255T2/en not_active Expired - Lifetime
- 2001-09-21 EP EP01971528A patent/EP1318792B1/en not_active Expired - Lifetime
- 2001-09-21 AT AT01971528T patent/ATE286387T1/en not_active IP Right Cessation
- 2001-09-21 US US10/380,620 patent/US20040048814A1/en not_active Abandoned
- 2001-09-21 ES ES01971528T patent/ES2234885T3/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2002024174A2 (en) | 2002-03-28 |
CA2423172A1 (en) | 2002-03-28 |
EP1318792B1 (en) | 2005-01-05 |
EP1318792A2 (en) | 2003-06-18 |
DE60108255D1 (en) | 2005-02-10 |
US20040048814A1 (en) | 2004-03-11 |
ES2234885T3 (en) | 2005-07-01 |
DE60108255T2 (en) | 2005-12-22 |
WO2002024174A3 (en) | 2002-09-26 |
PT1318792E (en) | 2005-04-29 |
ATE286387T1 (en) | 2005-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001291526A1 (en) | Sustained release composition containing clarithromycin | |
YU35302A (en) | Hidrogel-driven drug dosage form | |
AP2001002237A0 (en) | Hydrogel-driven drug dosage form. | |
YU36700A (en) | Oral pharmaceutical extended release dosage form | |
WO2003028660A3 (en) | Drug delivery devices and methods | |
CA2411277A1 (en) | Neurotoxin implant | |
WO2001043749A3 (en) | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration | |
WO2001008661A3 (en) | Opioid sustained-released formulation | |
AU1534699A (en) | Osmotic dosage form comprising first and second coats | |
IS4146A (en) | A pharmaceutical preparation for oral administration of proton pump blockers | |
GEP20053602B (en) | Aripiprazole for Oral Administration | |
AU6042796A (en) | Controlled release formulation having a preformed passageway | |
CA2352211A1 (en) | Sustained release matrix systems for highly soluble drugs | |
CA2193129A1 (en) | Transdermal drug delivery system | |
CA2298238A1 (en) | Controlled release by extrusion of solid amorphous dispersions of drugs | |
AU2002254036A1 (en) | Taste masked pharmaceutical compositions | |
GEP20053501B (en) | Core Tablet for Controlled Release of Gliclazide after Oral Administration | |
MY130332A (en) | Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer | |
ES2130081A1 (en) | Coated trimebutine maleate tablet | |
HK1047707A1 (en) | Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence | |
CA2383212A1 (en) | Controlled release oral dosage suitable for oral administration | |
AU3071300A (en) | Multiparticulate bisoprolol formulation | |
WO2001060343A3 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers | |
DE60004204D1 (en) | PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE ORAL ADMINISTRATION OF PHLOROGLUCINOL AND THE PRODUCTION THEREOF | |
MXPA06007511A (en) | Drug granule coatings that impart smear resistance during mechanical compression. |